Oral Biology: Hiki i nā hoʻololi peptide ke pani i ke āpau o ka lawe ʻana?

Pane wikiwiki

How cyclization, lipidation, kāʻili ʻana, and terminal modifications support oral peptide delivery—and what each one demands from your bioanalytical method.

ʻO ke Keʻakeʻa Hāʻawi waha - Pōkole a kikoʻī

ʻO nā peptide i hoʻololi ʻole ʻia i hāʻawi ʻia ma ka waha e kū i nā poho ʻehā ma mua o ka hiki ʻana i ka ʻōnaehana systemic: waika-mediated hydrolysis i loko o ka ʻōpū, hoʻohaʻahaʻa protease i loko o ka ʻōpū liʻiliʻi (serine, ʻo ka cysteine, a me nā ʻohana metalloprotease), impermeability mucosal i alakaʻi ʻia e ke kaumaha molekula, polarity, a uku, a me ka hoʻomaʻemaʻe ʻana i ka hepatic mua. The Frontiers Drug Delivery pharmacokinetic analysis i paʻi ʻia ma 2026 waiho i ka bioavailability waha no ka hapa nui o nā peptides therapeutic i hoʻololi ʻole ʻia ma lalo o 1-2% ʻoiai ma lalo o nā kūlana hoʻolālā i hoʻopaʻa ʻia., e hōʻike ana i ka hopena hui o kēia mau poho ʻehā.

ʻAʻohe hoʻolālā hoʻololi e hoʻopau i nā pale ʻehā i ka manawa like. Hoʻolālā kēlā me kēia hoʻolālā i kahi nāwaliwali ʻokoʻa, a ʻo nā moho waha ʻoi loa e hui pū ʻia ma mua o hoʻokahi. ʻO kēia ka mea a nā papa hoʻololi: Hoʻololi kēlā me kēia i ka ʻano analytical o ka mole i nā ala e pono e kamaʻilio pololei ʻia ma mua o ka hilinaʻi ʻana i ka ʻikepili pharmacokinetic GI..

Oral Biology: Hiki i nā hoʻololi peptide ke pani i ke āpau o ka lawe ʻana?

ʻO ka Cyclization — Laka Conformational a me kāna mea e koi ai i kāu hōʻike

Hoʻohuihui Peptide Hoʻomaikaʻi ka Cyclization i ka paʻa o ka peptide waha ma ka hoʻopau ʻana i ka N- a me C-termini i ʻike ʻia e nā exopeptidases ma ke ʻano he cleavage entry point. A 2017 ACS Chemical Reviews ka nānā ʻana o nā peptides cyclic i hoʻopaʻa waha ʻia hōʻike i ka wehe ʻana i kēia mau ʻōlelo - ma o nā paʻa amide head-to-tail, nā alahaka disulfide, thioether macrocycles, a i ʻole nā ​​loulou lactam - hoʻonui nui i ke kūʻē ʻana i ka hoʻohaʻahaʻa ʻana i nā wai o ka ʻōpū a me ka ʻōpū.. Hoʻopili ka hopena i ka hui ʻana o ka cyclization me ka N-methylation o nā paʻa amide, e hōʻemi ana i ka helu hāʻawi hydrogen bond a hoʻomaikaʻi i ka permeability membrane passive no nā molekole hiki ʻole ke hoʻohana i ka lawe ikaika..

ʻO ka hōʻoia hōʻoia i kēia manawa he nui. Octreotide (Mycapssa) he disulfide-bridged cyclic peptide i hōʻea i ka mākeke ma ke ʻano he ʻōlelo waha no ka acromegaly. ʻO ka Cyclosporine A a me ka voclosporin he mau immunosuppressants i hoʻopaʻa ʻia me ka bioavailability waha.. ʻOi aku nei, ka polokalamu Chugai LUNA18 cyclic peptide hōʻike ʻia ka bioavailability waha preclinical o 21-47% ma waena o nā ʻano holoholona ʻehā, he laulā hiki ʻole ke loaʻa me nā scaffolds laina.

Oral Biology: Hiki i nā hoʻololi peptide ke pani i ke āpau o ka lawe ʻana?

He aha kāu e ho'āʻo ai e mālama: Hoʻokumu nā peptides cyclic i nā ʻano hoʻohālike atypical i LC-MS/MS i hoʻohālikelike ʻia me kā lākou mau laina laina.. Hiki i ka scaffold paʻa ke hana i nā ʻāpana i loko o ke kumu a i ʻole nā ​​ʻano ʻano mokuʻāina he nui e paʻakikī i ke koho hoʻololi MRM. ʻOi aku koʻikoʻi, a 2025 Ka nānā ʻana o PMC i nā pale a me nā hoʻolālā peptide waha ʻike ʻia ʻaʻole pale loa ka cyclization i ka hoʻohaʻahaʻa ʻana i ka GI - hoʻolohi ia - ʻo ia hoʻi, ʻo ka peptide cyclic intact a me nā ʻano apo i wehe ʻia a i ʻole kekahi hapa hydrolyzed e hiki ke hui pū ʻia i loko o nā laʻana matrix GI.. Pono e hōʻike ʻia ke koho hoʻāʻo e kūʻē i kēia mau huahana degradation kikoʻī, ʻaʻole kūʻē wale i ka hope matrix endogenous.

Kuʻuna cyclic peptide synthesis ma ka unahi noiʻi pono e hoʻohālikelike ʻia ke kemika cyclization me nā pono o ka hōʻike ʻana o ka analyte. ʻO ka pōʻai disulfide, thioether macrocycles, a me nā apo lactam-bridged i kēlā me kēia mea e hōʻike i nā koi pūʻulu pale like ʻole i ka wā SPPS a me nā kiʻi paʻa like ʻole i ka hoʻomākaukau ʻana a me ka mālama ʻana o ka hana bioanalytical.

Lipidation — Hoʻopaʻa Albumin, Kālepa GI, a me ka paʻakikī Metabolite

Hoʻopili ka Lipidation i kahi waikawa momona - ʻoi aku ka maʻamau C14, C16, aiʻole C18 - i ka iwi kuamoʻo peptide ma o ka amide paʻa, ester, a i ʻole ka mea paʻa, i kekahi manawa ma o kahi loulou bifunctional. ʻO ka pōmaikaʻi pharmacokinetic mua ka reversible serum albumin binding. Hana ʻo Albumin ma ke ʻano he puʻu kahe e pale ana i ka peptide mai ka kānana renal a me ka hoʻomaʻemaʻe enzymatic ʻoiai e hoʻolōʻihi ana i ka hapalua o ke ola o ka plasma.. No nā papahana waha, Hāʻawi ka lipidation i kahi pōmaikaʻi hou: hiki ke hoʻonui i ka hui ʻana o ka membrane ma ka epithelium intestinal i ka hoʻomoʻa transcellular ma lalo o kekahi mau kūlana.

Ua hoʻohana ʻia ka mīkini i ka hopena lapaʻau i ka semaglutide (Ka lawaiʻa), ka mea i hoʻokomo i kahi diacid momona C18 i hoʻopili ʻia ma o kahi linker mini-PEG e mālama i ka pilina albumin kiʻekiʻe i ka wā e hiki ai ke hāʻawi waha me ka ʻōnaehana hoʻonui absorption SNAC.. ʻO ka GLP-1 analog MEDI7219, kūkulu ʻia ma AstraZeneca, lawe i ka pili pili: a 2025 PMC metabolite haʻawina ʻike hoike mai ma kahi o 60% o MEDI7219 i noho paʻa ma hope 2 hola o in vitro incubation ma nā kūlana GI simulated, ʻoi aku ka maikaʻi ma mua o ka GLP-1 i hoʻololi ʻole ʻia a i ʻole semaglutide ma lalo o nā kūlana like.

As kahi loiloi PMC piha o nā hoʻolālā lipidation peptide (2023) hōʻuluʻulu manaʻo, ʻAʻole pili ka lipid tag ʻaʻole wale i ka hapalua o ke ola akā i ke ʻano lua, pāpili membrane, a me ka hoʻopaʻa ʻana o ka mea hoʻokipa i nā ʻano e pono ke ʻike ʻia no kēlā me kēia mole. ʻO ka hoʻonui ʻia ʻana o ka lipophilicity e hoʻololi i ke ʻano o ka māhele ʻana o ka mole i ka wā o ka unuhi ʻana, i loaʻa nā hopena analytical pololei.

He aha kāu e ho'āʻo ai e mālama: Hōʻike nā peptides lipidated i ka hoʻopaʻa paʻa ʻole i ka plasticware, kolamu frits, a me nā ʻāpana autosampler ma nā haʻahaʻa haʻahaʻa. He kumu ʻike ʻia kēia o ka lawe ʻana a me ka calibration hewa i nā haʻawina PK hāʻawi waha, kahi i haʻahaʻa loa ai nā peptide makua ma hope o ka lawe ʻana. ʻO ke ala metabolic mai kahi peptide lipidated maʻamau ka deacylation (ka wehe ʻana i ka momona momona), nā huahana β-oxidation, a me nā ʻāpana ʻāpana iwi kuamoʻo peptide - hiki i kēia mau mea a pau ke hoʻohua i nā ʻano me nā hoʻololi nui ʻana.. A 2024 ʻIkepili IQVIA/PMC o ka hoʻopili ʻana i ka hōʻailona ma LC-ESI-MS ua hōʻoia ʻia e hiki ke hoʻohaʻahaʻa i ka hōʻailona analyte analyte i ka hoʻopili ʻana i ka ionization in-source ma waena o ka lāʻau lapaʻau a me nā ʻano metabolite.. ʻO ka matrix-matched calibrators a me ka hōʻike metabolite koʻikoʻi e HRMS e koi pinepine ʻia ma mua o ka hilinaʻi ʻana i ka helu ma muli o MRM..

Hoʻopaʻa paʻa, Hoʻopili, a me nā Kūlana Kūlana Kūlana

Stapled Peptides a me GI Paʻa

Hoʻokomo ʻo Peptide stapling i kahi alahaka covalent all-hydrocarbon ma waena o ʻelua koena - maʻamau i a me i +4 - e laka i ka peptide i loko o kahi hoʻohālikelike alpha-helical.. ʻO ka hopena conformational rigidity e hoʻomaikaʻi i ka pale ʻana i ka protease ma o ka hōʻike ʻana i kahi geometry substrate e mālama pono ʻia ka hapa nui o nā protease GI ma mua o ke kaulahao laina maʻalahi.. ʻO ka mea hoʻohana kumu mua ʻo ia ka intracellular protein-protein interaction inhibition - kahi papa pahuhopu i hiki ʻole ke loaʻa i nā molekole liʻiliʻi maʻamau a paʻakikī hoʻi i nā antibodies e komo - akā ua kākau ʻia nā hoʻomaikaʻi kūpaʻa GI ma waena o nā scaffolds..

ʻO ka 2015 ACS Molecular Pharmaceutics study on GI paʻa o 17 nā lāʻau peptide ua nānā pono i ka ʻokoʻa o nā hoʻolālā hoʻololi, me ka peptide stapling i pili i ka salmon calcitonin analogs, hoʻololi i ke kū'ē i ka hoʻohaʻahaʻa enzymatic i loko o nā ʻano wai o ka ʻōpū a me ka ʻōpū. Hōʻike ka ʻikepili i nā hoʻomaikaʻi kūpaʻa hiki ke ana, ʻoiai ʻoi aku ka liʻiliʻi o ka hoʻonui ʻana ma mua o ka cyclization ma waena o ka peptide set i nānā ʻia.

Nā peptides i hoʻopaʻa ʻia koi i kemika synthetic kiko'ī - maʻamau ka apo-pani metathesis (RCM) ma lalo o nā kūlana kūpono me ke kaʻina holoʻokoʻa - a hiki i ka scaffold i hoʻopaʻa ʻia i ka hopena ke hoʻohua i nā ʻāpana like like ʻole i ka wā o ka in vitro GI stability assays a in vivo sample analysis. ʻO ka hoʻoheheʻe ʻia i loko o ke kumu no ka hoʻohua ʻana i nā ion o ka huahana e like me ka pūhui makua he mea paʻakikī i ʻike ʻia, a me ka hōʻoia ʻana o ka HRMS-based o ke kūkulu paʻa paʻa ʻia ma mua o ka hana ʻana i kahi ʻano MRM maʻamau..

Hoʻolālā Hoʻohui

Peptide-lāʻau conjugates, peptide-polymer conjugates, a me ka peptide-carrier conjugates e hōʻike ana i kahi ʻāpana ākea kahi i hoʻopili ʻia ai kahi hoʻololi hana i ka peptide me kahi loulou kikoʻī i hoʻolālā ʻia e ola a i ʻole e ʻoki ʻia i loko o kahi kaiaolaola i wehewehe ʻia.. No nā noi hāʻawi waha, ʻO ka hoʻolālā conjugation e hoʻoholo inā hiki ke kūkulu paʻa i ka epithelium intestinal a me ka mea e hiki mai ana i ka mea hoʻopili a me ka uku i ka wā e hele ai..

ʻO nā conjugates cleavable i manaʻo ʻia e hoʻokuʻu i ka peptide ikaika i loko o ka ʻōpū liʻiliʻi e hoʻolauna i kahi kaʻina metabolic i manaʻo ʻia. Pono e hoʻohālikelike ʻia kēlā ʻano hana - he aha nā ʻano i hoʻokuʻu ʻia, i ka helu hea, ma lalo o ka luminal pH a me nā kūlana enzyme, a me ke ʻano o ka pūlima analytical o ka ʻāpana i hoʻihoʻi ʻia. ʻO nā conjugates paʻa i hoʻolālā ʻia e ola i ka transit GI a hoʻopaʻa paʻa ʻia i mua o kahi pilikia ʻē aʻe: e hōʻike ana i ka hana piha, ʻaʻole kahi huahana hoʻohaʻahaʻa, ʻo ia ka ʻano e hana ana i ka hōʻailona pharmacodynamic.

Hoʻololi ʻia ʻo Terminal - ʻO nā lanakila maʻalahi loa ka paʻakikī loa e ana

ʻO ka acetylation N-terminal a me ka C-terminal amidation kekahi o nā hoʻolālā hoʻolālā peptide stabilization i hoʻohana nui ʻia no ka mea he mea maʻalahi lākou.. Ma ka hoʻololi ʻana i ka amine manuahi ma ka N-terminus me kahi hui acetyl a hoʻololi i ka carboxyl C-terminal i kahi amide, hoʻopau ʻia nā wahi ʻike exopeptidase ʻelua. ʻO ka mole ka hopena ʻaʻole ia he substrate no nā aminopeptidases a i ʻole carboxypeptidases, ʻo ia ka hapa nui o ka hōʻino ʻana o ka peptide luminal.

Nā lawelawe hoʻololi C-terminal a Hoʻololi N-terminal ʻO nā lawelawe kekahi o nā mea i noi pinepine ʻia i nā papahana noiʻi e loiloi ana i ka kūpaʻa GI, pololei no ka mea he kiʻekiʻe ka hoʻomaikaʻi ʻana i ke kūpaʻa e pili ana i ka paʻakikī synthesis. Hoʻohui mau ʻia ka hoʻololi ʻana o ka terminal me nā hoʻolālā ʻē aʻe - hiki i kahi peptide cyclized ke lawe pū i ka iwi kuamoʻo N-methylated amide a i ʻole ke koena fluorinated e hōʻemi hou i ka polarity - e hoʻolilo iā lākou i mea modular ma mua o kahi hoʻolālā kūʻokoʻa..

He aha kāu e ho'āʻo ai e mālama: He liʻiliʻi ka ʻokoʻa nui ma waena o kahi terminal i hoʻololi ʻole ʻia a me kahi terminal acetylated a i ʻole amidated - 42.011 Da no ka acetylation, 0.984 Da no ka amidation. Ma kahi mea hoʻonā haʻahaʻa, ʻaʻole hiki ke hoʻoholo ʻia nā palapala i hoʻololi ʻia a hoʻololi ʻole ʻia. ʻOi aku koʻikoʻi, hiki i ka deamidation in-source a i ʻole artifactual acetylation i ka wā o ka lawelawe ʻana i ka laʻana a i ʻole ka electrospray ionization, e hana ana i nā hōʻailona hope e hoʻopilikia i ka helu ʻana o ke kūlana hoʻololi i manaʻo ʻia. No nā haʻawina kūpaʻa GI e nānā ana i ka hapa o ka peptide i hoʻololi hope ʻia i ka manawa, pono e hōʻoia ʻia ka hoʻāʻo ʻana e kūʻē i nā ʻano like ʻole demodified, ʻaʻole kūʻē wale i ka matrix background. Pono nā ʻano blanks me ka makua i hoʻololi ʻole ʻia i ka wā hōʻoia.

Hoʻopili pū ʻo Termini i ka hana paʻa i ka HPLC hoʻohuli. Hoʻonui ka C-terminus amidated i ka hydrophobicity e pili ana i ka ʻakika manuahi, e pili ana i ka paʻa chromatographic a me ka coefficient partition o ka peptide i nā hiʻohiʻona wai GI. Pono e ana kēia mau hopena, ʻaʻole i manaʻo ʻia, i ka unuhi ʻana i ka hoʻolālā hoʻololi ʻana i kahi kaʻina hou.

ʻO ka hana bioanalytical he pilikia hoʻololi

Ma nā papa hoʻololi, puka mai kahi ʻano kūlike: ʻO ka hoʻololi hoʻololi e hoʻomaikaʻi ai i ka kūpaʻa GI e hoʻololi pū i ka ʻano analytical o ka peptide i nā ala e koi ai i ka hoʻomohala ʻana i ke ʻano hoʻololi.. ʻO kahi ʻano LC-MS/MS maʻamau i hoʻomohala ʻia no nā peptides i hoʻololi ʻole ʻia ʻaʻole e hoʻololi maʻemaʻe i kahi cyclized., lipidated, hoʻopaʻa ʻia, a i ʻole ka analog i hoʻololi ʻia me ka ʻole o ka hana hōʻoia i kālele ʻia i nā pilikia kikoʻī hoʻololi.

ʻO ka ʻO ke alakaʻi a EMA i ka hoʻomohala ʻana a me ka hana ʻana i nā peptides synthetic koi ʻia ka hōʻike analytical o kahi mea lāʻau peptide synthetic e hoʻoponopono i ka nuipa mole, ka hōʻoia ʻana o ke kaʻina hana amino acid, a me ka maʻemaʻe e pili ana i ke ʻano molekala kikoʻī i manaʻo ʻia no ka hoʻohana ʻana. No nā peptides i hoʻololi ʻia, 'o ia ho'i, pono e ho'oka'awale ka pū'olo kiko'ī i ka hale i ho'ololi 'ia mai nā mea pili pili loa - nā puka i wehe 'ia., nā ʻano deacylated, nā ʻano deamidated - ʻaʻole wale mai nā haumia maʻamau.

Hōʻuluʻulu ka papa ma lalo nei i ka luʻi bioanalytical mua i hoʻokomo ʻia e kēlā me kēia papa hoʻololi a me ka pane hoʻomohala haʻahaʻa haʻahaʻa i manaʻo ʻia ma mua o ka hana ʻana i nā haʻawina GI PK.:

Hoʻololi

ʻO ka Luʻi Bioanalytical kumu mua

Pane ʻano liʻiliʻi loa

Poʻo i ka huelo ʻO nā Peptides Synthetic cyclization

ʻO ka hoʻoheheʻe ʻana i ka laina analog co-elution; ʻokiʻoki atypical

E hōʻike i ke koho koho vs. puka apo; e hoʻohana i ka HRMS e hōʻoia i nā hana hoʻololi

ʻO ka pōʻai disulfide Hana ʻia ʻo Peptide

ʻO ka disulfide scrambling i ka wā e lawelawe ana i ka laʻana; hoʻokumu dimer

Hoʻohui i ka TCEP inhibition a iodoacetamide alkylation; hōʻoia i nā kūlana mālama a pau

Lipidation

Hoʻopaʻa paʻa ʻole; deacylation metabolite interference; hoʻopaʻa haʻahaʻa

E hoʻohana i nā ipu aniani silanized; hoʻohui i ka mea pale; hōʻoia i ka hoʻopili ʻana i ka metabolite i nā lakio i manaʻo ʻia

Hoʻopaʻa paʻa (hydrocarbon)

ʻO ka decomposition i loko o ke kumu i ka ʻāpana ʻaʻole i hoʻopaʻa ʻia; envelop mokuʻāina hoʻoili lehulehu

E hōʻoia i ka intact mass e HRMS; e hoʻopololei i ka volta kumu e hōʻemi i ka decomposition

N-acetylation

Haʻahaʻa Δmass vs. ʻano deacetylated; acetylation artifactual i ke kumu

E hoʻokomo i ka palapala deacetylated ma ke ʻano he kiko kikoʻī i ka hōʻoia; hōʻoia ma nā haʻahaʻa kumu haʻahaʻa

C-amidation

Deamidation artifact ma ke kumu; kokoke-isobaric nuipaʻa i ka ʻakika manuahi

E hōʻoia e kūʻē i ka ʻakika manuahi; e nānā i ka hoʻokaʻawale manawa paʻa ma lalo o nā kūlana matrix āpau

PEGylation

Envelop hōʻailona polymeric ākea; hoemi i ka ionization pono

E hoʻohana i ka MS a i ʻole LC intact-molecule me ka UV backup; hōʻoia i ka linearity pane no kēlā me kēia alapiʻi PEG

Peptide PEGylation hoʻohana ʻia ma ke ʻano he hoʻolālā hoʻopaʻa i nā papahana waha e hōʻike ana i kahi hiʻohiʻona ʻano noiʻi koʻikoʻi. Hoʻokumu nā kaulahao PEG i ka māhele ʻana o nā ʻano mole - PEG 2000 me N = 45 hana hou i nā ʻāpana, ʻo kahi laʻana, hoʻopuka i kahi enveloppi ion polymeric ma mua o ka puʻupuʻu discrete - e paʻakikī i ka helu ʻana a me ka loiloi maʻemaʻe.. Haʻawina hoʻohana ka 2026 Nā ʻikepili o ka CRS ʻEhā Oral Peptide Workshop e like me ka mea i ʻike ʻia e ka PEGylation ka pōmaikaʻi hāʻawi waha i ka nui a hiki ke hōʻemi i ka piʻi ʻana o ka ʻōpū ma luna o ka paepae PEG molecular weight., e hoʻohui i kahi hoʻololi hoʻolālā hou aʻe e pono e hahai ʻia e ka ʻikena analytical.

ʻO ka ʻO ka loiloi hoʻolālā PMC ADME hoʻonohonoho pololei i kēia pilikia: ʻO ka lipidization a me nā hoʻolālā hoʻololi pili e hoʻomaikaʻi i ka ʻike kūpaʻa GI, akā, ʻo nā waiwai physicochemical like e kōkua ai i ka peptide e ola i ka lumen hiki ke hoʻopili i ka pono o ka unuhi ʻana a me ka pane ionization i ka matrix analytical., e koi ana i ka hōʻoia ʻana ma mua o ka manaʻo o ka hoʻololi ʻana o ke ʻano.

He aha ke ʻano o kēia no kāu kikoʻī Synthesis

ʻO ka hoʻoholo e hoʻokomo i kekahi o kēia mau papa hoʻololi i kahi papahana peptide waha e hana i kahi koi kikoʻī o lalo e pono e wehewehe ʻia ma ka synthesis.. Pono ka hoʻololi ʻana ma kahi regiochemistry i wehewehe ʻia a lawa pono no ka hana analytical e pili ana.. Hāʻawi ʻia kahi peptide cyclic me ka macrolactamization piha ʻole, he peptide lipidated me heterogeneous fatty acid regiochemistry, a i ʻole kahi analog i hoʻololi ʻia me ka capping piha ʻole e hana i nā kiʻi kālaiʻike ʻaʻole hiki ke hoʻokaʻawale ʻia mai ka nalo paʻa maoli ʻana i kahi hōʻike kūpaʻa GI..

ʻO ia ke ʻano o ka synthesis a me ka hoʻolālā analytical ʻaʻole ia he mau ʻanuʻu kaʻina - he mau palena like ia e pono e hoʻohālikelike ʻia.. Hoʻoholo ʻia ka ʻōlelo kikoʻī maʻemaʻe liʻiliʻi loa no kahi peptide noiʻi hāʻawi waha e ka mea i hiki ke hoʻokaʻawale ʻia ka hoʻopaʻa ʻana i lalo., ʻaʻole wale ma ka mea hiki ke hoʻokō i ka synthesis. ʻO kahi haumia e hui pū ʻia me ka hoʻololi i manaʻo ʻia ma lalo o nā kūlana GI assay matrix he pilikia koʻikoʻi ma mua o ka haumia like i ʻike maʻemaʻe ʻia i ka holo maʻemaʻe HPLC pololei..

Ka wehewehe ʻana i ka ʻae ʻana o ka synthesis no nā pūhui noiʻi hāʻawi waha - hoʻololi hoʻololi, hōʻoia regiochemistry, hoʻololi-specific impurity profile, a me ka counterion - koi i ka mea kūʻai aku e pili ana i nā kemika kūlohelohe a me nā ʻano analytical. Hiki i nā polokalamu ma MOL Changes e hana pū ana me nā moho peptide i hoʻololi ʻia ke noi i kahi loiloi kūpono ʻenehana e kamaʻilio ana i ke ala synthesis., hoʻololi i nā manaʻolana hua, a me ka ʻano hōʻailona QC no ke kūkulu kikoʻī e noʻonoʻo ʻia nei.


ʻO MOL Changes kahi peptide synthesis a hoʻololi i ka lawelawe lawelawe. Hōʻike kēia ʻatikala i nā palapala hoʻonaʻauao a me nā palapala hoʻoponopono i paʻi ʻia a ʻaʻole pono e heluhelu ʻia ma ke ʻano he koi lapaʻau. Loaʻa i ka MOL Changes kahi makemake pāʻoihana i nā lawelawe hoʻololi peptide i kuhikuhi ʻia ma kēia ʻatikala.

Jinling Liu

Jinling Liu

Kaʻina hana R&D a me ka Mea Hana Hana Kaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.

Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana